Drug Trial Radar · NCT01369355
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Last checked: Nov 20, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,282
Actual
Start
Sep 13, 2011
Primary completion
Jun 10, 2015
Study completion Oct 1, 2019
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 8, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy and safety of 2 maintenance regimens of ustekinumab administered subcutaneously to patients with moderately to severely active Crohn's disease who responded to treatment with intravenous ustekinumab in studies CNTO1275CRD3001 and CNTO1275CRD3002, compared to subcutaneously administered placebo.
Conditions
- Crohn's Disease
- Colitis
- IBD
- Inflammatory Bowel Disease
Interventions
Placebo SCDrug
Placebo will be administered subcutaneously.
Placebo IVDrug
Placebo will be administered as a single Intravenous infusion at week 0.
Ustekinumab 90 mg SC q8wDrug
Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.
Ustekinumab 130 mg IVDrug
Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.
Ustekinumab 90 mg SC q12wDrug
Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Clinical Remission at Week 44Time frame: Week 44
Locations
220 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
San Carlos, California
Site not named
San Diego, California
Site not named
Santa Monica, California
Site not named
Lone Tree, Colorado
Site not named
New Haven, Connecticut
Site not named
Boca Raton, Florida
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Naples, Florida
Site not named
Weston, Florida
Site not named
Winter Park, Florida
Site not named
Atlanta, Georgia
Site not named
Decatur, Georgia
Site not named
Macon, Georgia
Site not named
Idaho Falls, Idaho
Site not named
Chicago, Illinois
Site not named
Evanston, Illinois
Site not named
Clive, Iowa
Site not named
Pratt, Kansas
Site not named
Crestview Hills, Kentucky
Site not named
Lexington, Kentucky
Site not named
Louisville, Kentucky
Site not named
Baton Rouge, Louisiana
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Chevy Chase, Maryland
Site not named
Towson, Maryland
Site not named
Boston, Massachusetts
Site not named
Worcester, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Chesterfield, Michigan
Site not named
Detroit, Michigan
Site not named
Troy, Michigan
Site not named
Ypsilanti, Michigan
Site not named
Rochester, Minnesota
Site not named
Jackson, Mississippi
Site not named
Ocean Springs, Mississippi
Showing 40 of 220 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.